JP2017158561A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017158561A5 JP2017158561A5 JP2017077422A JP2017077422A JP2017158561A5 JP 2017158561 A5 JP2017158561 A5 JP 2017158561A5 JP 2017077422 A JP2017077422 A JP 2017077422A JP 2017077422 A JP2017077422 A JP 2017077422A JP 2017158561 A5 JP2017158561 A5 JP 2017158561A5
- Authority
- JP
- Japan
- Prior art keywords
- inflammatory
- seq
- composition according
- composition
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 7
- 230000003110 anti-inflammatory Effects 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 200000000018 inflammatory disease Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 claims 1
- 201000004624 dermatitis Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
Description
その結果、ペプチド配列番号1〜5、配列番号7、配列番号9、配列番号10、配列番号12、配列番号13、配列番号15、配列番号17〜27、配列番号29、配列番号30、配列番号32〜53、配列番号55〜60、配列番号67、配列番号68、配列番号70、配列番号72〜82、配列番号84〜92、配列番号94、配列番号99〜112、配列番号114、配列番号127〜144、配列番号146、配列番号148、配列番号149、配列番号151、及び配列番号153〜161が、対照群であるLPSのみを処理したグループに比べ、TNF−αを減少させるようであった。
また、配列番号1〜5、配列番号7、配列番号9、配列番号10、配列番号12、配列番号13、配列番号15、配列番号17〜23、配列番号25〜27、配列番号29、配列番号30、配列番号33〜43、配列番号156、配列番号157及び配列番号159が、LPS及びエストロゲンで処理したグループに比べ、TNF−αの発現レベルを減少させるペプチドであると選別された。
また、配列番号1〜5、配列番号7、配列番号9、配列番号10、配列番号12、配列番号13、配列番号15、配列番号17〜23、配列番号25〜27、配列番号29、配列番号30、配列番号33〜43、配列番号156、配列番号157及び配列番号159が、LPS及びエストロゲンで処理したグループに比べ、TNF−αの発現レベルを減少させるペプチドであると選別された。
Claims (5)
- (a)配列番号48又は106のアミノ酸配列、または
(b)(a)に規定されたアミノ酸配列と少なくとも90%の配列同一性を有するアミノ酸配列
から成るペプチドを活性成分として含む、抗炎症組成物。 - 皮膚炎症の改善用または予防用の化粧品組成物である、請求項1に記載の抗炎症組成物。
- 炎症性疾患の治療または予防のための医薬組成物である、請求項1に記載の抗炎症組成物。
- 炎症の治療または予防のための食品組成物である、請求項1に記載の抗炎症組成物。
- 請求項1〜4のうちいずれか1項に記載の組成物;及び
前記組成物の投与量、投与経路、投与回数及び適応症の少なくとも1つを含む指示書
を含む、炎症性疾患の治療用または予防用のキット。
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120079096A KR20140012385A (ko) | 2012-07-20 | 2012-07-20 | 항염증 활성을 갖는 펩티드 및 이를 포함하는 염증질환 치료용 조성물 |
KR10-2012-0079096 | 2012-07-20 | ||
KR10-2012-0089161 | 2012-08-14 | ||
KR10-2012-0089167 | 2012-08-14 | ||
KR1020120089162A KR20140022698A (ko) | 2012-08-14 | 2012-08-14 | 텔로머라제 펩티드를 포함하는 염증 예방 또는 억제용 조성물 |
KR20120089161 | 2012-08-14 | ||
KR10-2012-0089162 | 2012-08-14 | ||
KR1020120089167A KR20140022699A (ko) | 2012-08-14 | 2012-08-14 | 텔로머라제 펩티드를 포함하는 염증 예방 또는 억제용 조성물 |
KR20120104144 | 2012-09-19 | ||
KR10-2012-0104207 | 2012-09-19 | ||
KR10-2012-0104144 | 2012-09-19 | ||
KR20120104207 | 2012-09-19 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015521997A Division JP6352911B2 (ja) | 2012-07-20 | 2013-03-15 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019075635A Division JP6788062B2 (ja) | 2012-07-20 | 2019-04-11 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2017158561A JP2017158561A (ja) | 2017-09-14 |
JP2017158561A5 true JP2017158561A5 (ja) | 2018-11-22 |
JP6514259B2 JP6514259B2 (ja) | 2019-05-15 |
Family
ID=47882177
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015521997A Active JP6352911B2 (ja) | 2012-07-20 | 2013-03-15 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
JP2017077422A Active JP6514259B2 (ja) | 2012-07-20 | 2017-04-10 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
JP2019075635A Active JP6788062B2 (ja) | 2012-07-20 | 2019-04-11 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
JP2020181780A Active JP7128246B2 (ja) | 2012-07-20 | 2020-10-29 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
JP2022130519A Active JP7440581B2 (ja) | 2012-07-20 | 2022-08-18 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
JP2024021407A Pending JP2024056904A (ja) | 2012-07-20 | 2024-02-15 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015521997A Active JP6352911B2 (ja) | 2012-07-20 | 2013-03-15 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019075635A Active JP6788062B2 (ja) | 2012-07-20 | 2019-04-11 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
JP2020181780A Active JP7128246B2 (ja) | 2012-07-20 | 2020-10-29 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
JP2022130519A Active JP7440581B2 (ja) | 2012-07-20 | 2022-08-18 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
JP2024021407A Pending JP2024056904A (ja) | 2012-07-20 | 2024-02-15 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
Country Status (8)
Country | Link |
---|---|
US (6) | US20150125438A1 (ja) |
EP (3) | EP3428182B1 (ja) |
JP (6) | JP6352911B2 (ja) |
KR (2) | KR20150031413A (ja) |
CN (3) | CN109777791B (ja) |
ES (2) | ES2693321T3 (ja) |
TW (4) | TWI647311B (ja) |
WO (1) | WO2014012683A1 (ja) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9527888B2 (en) | 2012-05-11 | 2016-12-27 | Gemvax & Kael Co., Ltd. | Anti-inflammatory peptides and composition comprising the same |
US10967000B2 (en) | 2012-07-11 | 2021-04-06 | Gemvax & Kael Co., Ltd. | Cell-penetrating peptide, conjugate comprising same and composition comprising same |
US20150125438A1 (en) | 2012-07-20 | 2015-05-07 | Sang Jae Kim | Anti-Inflammatory Peptides and Composition Comprising the Same |
ES2802253T3 (es) | 2012-09-19 | 2021-01-18 | Gemvax & Kael Co Ltd | Péptido de penetración celular, conjugado que comprende el mismo y composición que comprende el conjugado |
US9572900B2 (en) | 2012-09-19 | 2017-02-21 | Gemvax & Kael Co., Ltd. | Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate |
PT2970412T (pt) | 2013-03-15 | 2022-09-13 | Promega Corp | Ativação de bioluminescência por complementação estrutural |
RU2677277C2 (ru) | 2013-06-07 | 2019-01-16 | Джемвакс Энд Каэл Ко., Лтд. | Биологические маркеры, которые могут быть использованы в иммунотерапии рака |
EP3011967B1 (en) | 2013-06-21 | 2020-06-17 | Gemvax & Kael Co., Ltd. | Hormone secretion regulator, composition containing same, and method for controlling hormone secretion using same |
WO2015005723A1 (ko) * | 2013-07-12 | 2015-01-15 | 주식회사 카엘젬백스 | 세포 투과성 펩티드 및 이를 포함하는 컨쥬게이트 |
KR102494803B1 (ko) | 2013-11-22 | 2023-02-06 | 주식회사 젬백스앤카엘 | 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 |
US11058744B2 (en) | 2013-12-17 | 2021-07-13 | Gemvax & Kael Co., Ltd. | Composition for treating prostate cancer |
JP6420459B2 (ja) * | 2014-04-11 | 2018-11-07 | ジェムバックス アンド カエル カンパニー,リミティド | 線維症抑制活性を有するペプチド及びこれを含む組成物 |
CN106659149B (zh) | 2014-04-30 | 2020-05-19 | 珍白斯凯尔有限公司 | 用于器官、组织或细胞移植的组合物、试剂盒和移植方法 |
EP3193906B1 (en) * | 2014-09-18 | 2020-11-11 | The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of Holy and Undiv. Trinity of Queen Elizabeth near Dublin | Use of peptide inhibitors of il-36 proteolytic processing for the treatment and/or reduction of inflammation |
KR102413243B1 (ko) | 2014-12-23 | 2022-06-27 | 주식회사 젬백스앤카엘 | 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물 |
CN107405380B (zh) | 2015-02-27 | 2021-04-20 | 珍白斯凯尔有限公司 | 用于预防听觉损伤的肽及其包含该肽的组合物 |
KR101662438B1 (ko) | 2015-04-07 | 2016-10-04 | 가톨릭대학교 산학협력단 | X형 구조의 dna를 유효성분으로 포함하는 아토피 피부염 예방 또는 치료용 조성물 |
KR101734529B1 (ko) | 2015-05-08 | 2017-05-11 | 건국대학교 산학협력단 | 패혈증 치료제의 스크리닝 방법 및 패혈증 치료용 약학 조성물 |
ES2879641T3 (es) | 2015-05-26 | 2021-11-22 | Gemvax & Kael Co Ltd | Octapéptidos antiinflamatorias, antifibróticos y cicatrizantes de heridas y las composiciones que los contienen |
ES2886946T3 (es) | 2015-07-02 | 2021-12-21 | Gemvax & Kael Co Ltd | Péptido con efecto antiviral y composición que lo contiene |
US10858397B2 (en) | 2015-08-28 | 2020-12-08 | The Medical College Of Wisconsin, Inc. | Peptide inhibitors of telomerase translocation and therapeutic uses thereof |
CA3006044A1 (en) * | 2015-09-09 | 2017-03-16 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with cerebro-craniofacial health |
US10898540B2 (en) | 2016-04-07 | 2021-01-26 | Gem Vax & KAEL Co., Ltd. | Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same |
KR101831888B1 (ko) * | 2016-04-15 | 2018-04-16 | (주)케어젠 | 항염증 활성을 갖는 펩타이드 및 이의 용도 |
KR101887577B1 (ko) | 2016-10-19 | 2018-09-10 | (주)케어젠 | 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도 |
AU2017382037B2 (en) * | 2016-12-22 | 2022-03-10 | Centre Hospitalier Universitaire De Montpellier | New stapled-peptides and uses thereof |
JP6601849B2 (ja) * | 2017-08-21 | 2019-11-06 | 株式会社大一商会 | 遊技機 |
JP6601848B2 (ja) * | 2017-08-21 | 2019-11-06 | 株式会社大一商会 | 遊技機 |
KR102092843B1 (ko) * | 2018-08-30 | 2020-03-24 | 충남대학교 산학협력단 | 암 예방 또는 치료용 펩타이드 및 이의 용도 |
KR102274658B1 (ko) * | 2018-11-16 | 2021-07-09 | 주식회사 카인사이언스 | 염증성 피부질환 치료용 펩타이드 및 이의 용도 |
KR102032945B1 (ko) * | 2018-12-03 | 2019-10-16 | 순천대학교 산학협력단 | 항염증 활성을 나타내는 펩타이드 및 이를 유효성분으로 포함하는 항염증용 조성물 |
KR102146937B1 (ko) * | 2018-12-11 | 2020-08-21 | 대한민국 | 왕사마귀로부터 유래된 테노데라신-1 펩타이드, 이를 유효성분으로 포함하는 항균, 항진균 또는 항염증용 조성물 |
KR102266613B1 (ko) * | 2020-09-21 | 2021-06-18 | 자안바이오 주식회사 | 항염증 활성을 갖는 신규한 펩티드 및 이의 용도 |
WO2022167656A1 (en) * | 2021-02-08 | 2022-08-11 | Bacoba Ag | Treatment of skin disorders |
WO2023214802A1 (ko) * | 2022-05-03 | 2023-11-09 | 한국생명공학연구원 | 신규 펩타이드 및 이의 항염 및 재생 용도 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1523965A (en) * | 1976-03-19 | 1978-09-06 | Ici Ltd | Pharmaceutical compositions containing steroids |
DE4330664A1 (de) * | 1993-09-10 | 1995-03-16 | Beiersdorf Ag | Verwendungen von Pflanzenölen |
CZ3497A3 (en) * | 1994-07-07 | 1997-10-15 | Geron Corp | Rna component of mammal telomerase, oligonucleotide, recombinant expression plasmid containing the oligonucleotide, process for preparing eukaryotic host cell, process for preparing a recombinant telomerase enzyme |
CA2258285C (en) * | 1996-06-25 | 2002-11-26 | Anthony Marfat | Substituted indazole derivatives and their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors |
US6610839B1 (en) * | 1997-08-14 | 2003-08-26 | Geron Corporation | Promoter for telomerase reverse transcriptase |
AU734089B2 (en) * | 1996-10-01 | 2001-06-07 | Geron Corporation | Human telomerase catalytic subunit |
JP2002514928A (ja) * | 1997-07-01 | 2002-05-21 | キャンビア バイオシステムス リミティド ライアビリティー カンパニー | 脊椎動物テロメラーゼ遺伝子およびタンパク質ならびにその使用 |
US7030211B1 (en) | 1998-07-08 | 2006-04-18 | Gemvax As | Antigenic peptides derived from telomerase |
KR20040041575A (ko) * | 2001-07-31 | 2004-05-17 | 칼 페터 쇠더스트룀 | 면역반응의 모듈화 조성물 및 모듈화 방법 |
AU2002323110A1 (en) * | 2001-08-08 | 2003-02-24 | Incyte Genomics, Inc. | Proteins associated with cell growth, differentiation, and death |
US8492438B2 (en) * | 2002-04-26 | 2013-07-23 | Asan Laboratories Company (Cayman), Limited | Treatment skin disorders |
EP1625220A2 (en) * | 2003-05-01 | 2006-02-15 | MUSC Foundation For Research Development | An autologous upregulation mechanism allowing optimized cell type-specific and regulated gene expression cells |
CN101011571A (zh) * | 2006-03-13 | 2007-08-08 | 上海交通大学医学院 | GADD45 β 蛋白及其抑制剂在类风湿关节炎中的应用 |
US9487574B2 (en) * | 2006-09-21 | 2016-11-08 | Vaxil Biotherapeutics Ltd. | Antigen specific multi epitope vaccines |
WO2008043760A1 (en) * | 2006-10-12 | 2008-04-17 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Telomerase reverse transcriptase fusion protein, nucleotides encoding it, and uses thereof |
EP2155703A1 (en) | 2007-05-18 | 2010-02-24 | Inhibox Ltd. | Bicyclosulfonyl acid (bcsa) compounds and their use as therapeutic agents |
WO2009025871A1 (en) * | 2007-08-23 | 2009-02-26 | University Of Medicine And Dentistry Of Nj | Telomerase reverse transcriptase variant |
GB2455539B (en) | 2007-12-12 | 2012-01-18 | Cambridge Entpr Ltd | Anti-inflammatory compositions and combinations |
HUE030984T2 (en) * | 2008-06-16 | 2017-06-28 | Mediolanum Farm S P A | Antitumor immunotherapy |
US8252282B2 (en) * | 2008-06-19 | 2012-08-28 | University Of Medicine & Dentistry Of New Jersey | Nuclear telomerase reverse transcriptase variant |
US20110183925A1 (en) | 2008-09-22 | 2011-07-28 | Nisshin Pharma Inc. | Anti-inflammatory peptide |
EP2337795A2 (en) | 2008-10-01 | 2011-06-29 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
EP2536830B1 (en) * | 2010-02-16 | 2019-07-17 | Ultimovacs AS | Polypeptides |
KR101284772B1 (ko) | 2011-05-24 | 2013-07-17 | 정종문 | 항염증, 진통효과를 가지는 기능성 식품 조성물 |
KR20120133661A (ko) | 2011-05-31 | 2012-12-11 | 주식회사 바이오포트코리아 | 아스타잔틴을 포함하는 항염증제 |
US9527888B2 (en) | 2012-05-11 | 2016-12-27 | Gemvax & Kael Co., Ltd. | Anti-inflammatory peptides and composition comprising the same |
US20150125438A1 (en) | 2012-07-20 | 2015-05-07 | Sang Jae Kim | Anti-Inflammatory Peptides and Composition Comprising the Same |
US9572900B2 (en) | 2012-09-19 | 2017-02-21 | Gemvax & Kael Co., Ltd. | Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate |
ES2802253T3 (es) | 2012-09-19 | 2021-01-18 | Gemvax & Kael Co Ltd | Péptido de penetración celular, conjugado que comprende el mismo y composición que comprende el conjugado |
TWI598441B (zh) | 2012-09-19 | 2017-09-11 | 傑姆維克斯&凱爾有限公司 | 穿膜胜肽以及包含該胜肽之共軛物及組成物(四) |
RU2677277C2 (ru) * | 2013-06-07 | 2019-01-16 | Джемвакс Энд Каэл Ко., Лтд. | Биологические маркеры, которые могут быть использованы в иммунотерапии рака |
WO2015005723A1 (ko) | 2013-07-12 | 2015-01-15 | 주식회사 카엘젬백스 | 세포 투과성 펩티드 및 이를 포함하는 컨쥬게이트 |
ES2879641T3 (es) | 2015-05-26 | 2021-11-22 | Gemvax & Kael Co Ltd | Octapéptidos antiinflamatorias, antifibróticos y cicatrizantes de heridas y las composiciones que los contienen |
WO2017066349A1 (en) | 2015-10-13 | 2017-04-20 | Symic Ip, Llc | Ve-cadherin binding bioconjugate |
-
2013
- 2013-03-05 US US14/400,322 patent/US20150125438A1/en not_active Abandoned
- 2013-03-15 CN CN201910110866.0A patent/CN109777791B/zh active Active
- 2013-03-15 EP EP18187426.4A patent/EP3428182B1/en active Active
- 2013-03-15 JP JP2015521997A patent/JP6352911B2/ja active Active
- 2013-03-15 KR KR1020147034319A patent/KR20150031413A/ko active Application Filing
- 2013-03-15 WO PCT/EP2013/055326 patent/WO2014012683A1/en active Application Filing
- 2013-03-15 CN CN202311502816.XA patent/CN117551631A/zh active Pending
- 2013-03-15 EP EP21162575.1A patent/EP3896078A1/en active Pending
- 2013-03-15 ES ES13709221T patent/ES2693321T3/es active Active
- 2013-03-15 ES ES18187426T patent/ES2871899T3/es active Active
- 2013-03-15 CN CN201380038045.1A patent/CN104470947B/zh active Active
- 2013-03-15 EP EP13709221.9A patent/EP2875042B1/en active Active
- 2013-03-15 KR KR1020207019525A patent/KR102302392B1/ko active IP Right Grant
- 2013-05-01 TW TW106121753A patent/TWI647311B/zh active
- 2013-05-01 TW TW108101145A patent/TWI700290B/zh active
- 2013-05-01 TW TW102115615A patent/TWI658141B/zh active
- 2013-05-01 TW TW109115548A patent/TWI779287B/zh active
-
2017
- 2017-04-05 US US15/479,746 patent/US20170275603A1/en not_active Abandoned
- 2017-04-10 JP JP2017077422A patent/JP6514259B2/ja active Active
-
2019
- 2019-04-11 JP JP2019075635A patent/JP6788062B2/ja active Active
-
2020
- 2020-01-17 US US16/746,018 patent/US20200140832A1/en not_active Abandoned
- 2020-03-13 US US16/818,001 patent/US11098294B2/en active Active
- 2020-10-29 JP JP2020181780A patent/JP7128246B2/ja active Active
-
2021
- 2021-07-30 US US17/389,671 patent/US11905536B2/en active Active
-
2022
- 2022-08-18 JP JP2022130519A patent/JP7440581B2/ja active Active
-
2024
- 2024-01-12 US US18/411,838 patent/US20240158768A1/en active Pending
- 2024-02-15 JP JP2024021407A patent/JP2024056904A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2017158561A5 (ja) | ||
Di Caprio et al. | Anti-inflammatory properties of low and high doxycycline doses: an in vitro study | |
JP2018509388A5 (ja) | ||
MX2019012884A (es) | Terapia de combinacion. | |
JP2015517488A5 (ja) | ||
RU2020126034A (ru) | Векторы фактора fviii на основе аденоассоциированных вирусов, соответствующие вирусные частицы и содержащие их терапевтические композиции | |
JP2017503820A5 (ja) | ||
RU2020123893A (ru) | Эскетамин для лечения депрессии | |
JPWO2019156137A5 (ja) | ||
JP2013542185A5 (ja) | ||
JP2019533722A5 (ja) | ||
MY201105A (en) | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus | |
LeMessurier et al. | Antimicrobial peptides alter early immune response to influenza A virus infection in C57BL/6 mice | |
EP4279128A3 (en) | Novel antibody binding to tfpi and composition comprising the same | |
JPWO2019107530A5 (ja) | ||
JP2017531673A5 (ja) | ||
JP2019531293A5 (ja) | ||
EA201300421A1 (ru) | Комбинированная терапия для лечения инфекции hcv | |
Ellerhoff et al. | Novel epi-virotherapeutic treatment of pancreatic cancer combining the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus | |
EA202190310A1 (ru) | Белок для лечения воспалительных заболеваний | |
WO2020219766A8 (en) | Compositions useful in treatment of rett syndrome | |
JP2018524306A5 (ja) | ||
Ke et al. | Curcumin-activated autophagy plays a negative role in its anti-osteoclastogenic effect | |
JP2019507786A5 (ja) | ||
Liu et al. | Chrysin ameliorates influenza virus infection in the upper airways by repressing virus-induced cell cycle arrest and mitochondria-dependent apoptosis |